SCHEMBL354124

SCHEMBL354124

COC(=O)c1ccc2c(c1)CCC(S(=O)(=O)C(F)(F)F)=C2

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 2/20 0.40
PDK2 Q15119 2/20 0.38
SRD5A1 P18405 1/20 0.37
SRD5A2 P31213 1/20 0.37
CA12 O43570 1/20 0.37
CA1 P00915 1/20 0.37
CA2 P00918 1/20 0.37
CA7 P43166 1/20 0.37
XDH P47989 1/20 0.37
CA9 Q16790 1/20 0.37
CA14 Q9ULX7 1/20 0.37
MAPK14 Q16539 1/20 0.37
TRPA1 O75762 1/20 0.37
KDM4E B2RXH2 3/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
HSD17B10 Q99714 1/20 0.36
PTPRC P08575 1/20 0.36
TP53 P04637 1/20 0.36
CRBN Q96SW2 1/20 0.36
HPGD P15428 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL354057 0.81 NOTUM (0.39) NOTUMPDK2SRD5A1SRD5A2CA12
SCHEMBL10247077 0.76 SRD5A1 (0.46) SRD5A1SRD5A2CA12CA1CA2
SCHEMBL25107063 0.74 CA1 (0.44) SRD5A1SRD5A2CA12CA1CA2
SCHEMBL29600409 0.72 CA12 (0.41) NOTUMPDK2SRD5A1SRD5A2CA12
SCHEMBL18144740 0.71 CYP1A2 (0.43) PDK2SRD5A1SRD5A2CA12CA1
SCHEMBL31498196 0.71 NOTUM (0.49) NOTUMPDK2CA12CA1CA2
SCHEMBL354113 0.71 PDK2 (0.39) NOTUMPDK2CA12CA1CA2
SCHEMBL10247300 0.70 TDP1 (0.50) SRD5A1SRD5A2CA12CA1CA2
SCHEMBL9644030 0.70 CA1 (0.55) SRD5A1SRD5A2CA12CA1CA2
SCHEMBL354551 0.69 PTGS2 (0.55) CA1CA2KDM4ESMN1; SMN2TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140243335-A1 SUBSTITUTED HYDOXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2014-08-28 US disclosed
WO-2012012322-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2012-01-26 WO disclosed
US-20120015943-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACUTICALS, INC. (US) 2012-01-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120015943-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF HDAC6, HDAC1, HDAC2 NOTUM 3808/4885PDK2 1447/4885SRD5A1 1128/4885
US-20140243335-A1 SUBSTITUTED HYDOXAMIC ACIDS AND USES THEREOF HDAC6, HDAC1, H1-3 NOTUM 3191/4885PDK2 493/4885SRD5A1 1078/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.